Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00749411 · ClinicalTrials.gov registry record · Phase 2
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
A Phase 2 study of Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
- 12
- Study locations
NCT00749411 is a Phase 2 study of Pulmonary Disease, Chronic Obstructive that has completed, run by GlaxoSmithKline. The registered enrollment target is 61 participants, below the 1,043-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (94% lower). The trial reports 12 study locations across 11 states.
The verdict
NCT00749411, a Phase 2 study of Pulmonary Disease, Chronic Obstructive, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
- 12
- Study locations
Study Summary
The purpose of this study is the evaluate the safety and tolerability of repeat dosing of the combination of inhaled GSK233705 and GW642444 administered once-daily in subjects with COPD.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG GSK233705/GW642444
Study Locations (12)
South Carolina
- GSK Investigational Site - Greenville
- GSK Investigational Site - Spartanburg
Alabama
- GSK Investigational Site - Mobile
Colorado
- GSK Investigational Site - Wheat Ridge
Maine
- GSK Investigational Site - Biddeford
Missouri
- GSK Investigational Site - St Louis
New Jersey
- GSK Investigational Site - Summit
Oregon
- GSK Investigational Site - Medford
Pennsylvania
- GSK Investigational Site - Erie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2008-11-13 |
| Est. Completion | 2009-02-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00749411
The ClinicalTrials.gov registry entry for NCT00749411 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,043-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (94% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00749411 reports 12 study locations spanning 11 distinct geographic areas - top geographies include South Carolina, Alabama, Colorado.
Frequently Asked Questions
What is clinical trial NCT00749411 about?
NCT00749411 is a clinical study titled "Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD". The purpose of this study is the evaluate the safety and tolerability of repeat dosing of the combination of inhaled GSK233705 and GW642444 administered once-daily in subjects with COPD.
What is the current status of trial NCT00749411?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2008-11-13. Estimated completion is 2009-02-12.
What conditions does trial NCT00749411 study?
This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive.
What interventions are being tested in trial NCT00749411?
The interventions under investigation include: Placebo (DRUG), GSK233705/GW642444 (DRUG).
Who is sponsoring clinical trial NCT00749411?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00749411 being conducted?
This trial has 12 study locations across Alabama, Colorado, Maine, Missouri, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Disease, Chronic Obstructive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component
COMPLETED · Phase 2
-
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 2
-
Cathelicidin and Vitamin D: Impact on Populations At-Risk and With COPD
COMPLETED · Phase 2
-
A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 2
-
A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.
COMPLETED · Phase 2
-
Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.